Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Date publication

avril 2016

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr DEBIEUVRE Didier , Pr WESTEEL Virginie

Tous les auteurs :
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26777916

Résumé

The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme funded by the French National Cancer Institute.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, genetics, Female, France, epidemiology, Gene Expression Profiling, Gene Rearrangement, Humans, Lung Neoplasms, genetics, Male, Middle Aged, Multivariate Analysis, Mutation, Phosphatidylinositol 3-Kinases, genetics, Prospective Studies, Proto-Oncogene Proteins B-raf, genetics, Proto-Oncogene Proteins p21(ras), genetics, Receptor Protein-Tyrosine Kinases, genetics, Receptor, Epidermal Growth Factor, genetics, Receptor, ErbB-2, genetics, Young Adult

Référence

Lancet. 2016 Apr;387(10026):1415-26